December 4, 2014 Below is a pdf for Issue 792 of the Medical Technology Stock Letter. “End of Another Year, This One Surprises (Again)” [gview file=http://www.bioinvest.com/wp-content/uploads/2014/12/MTSL-792-Dec-4-2014.pdf save=”1″]
November 6, 2014 Below is a pdf for Issue 790 of the Medical Technology Stock Letter. [gview file=http://www.bioinvest.com/wp-content/uploads/2014/11/MTSL-790-Nov-6-2014.pdf save=”1″]
November 6, 2014 Biotech Watchlist Update: Small-Cap Biotechs Struggle to Rebound, but Investors Remain Enchanted by Big Pharma’s Solid Returns When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies haven’t yet entirely recouped[…]
September 18, 2014 Below is a pdf for Issue 787 of the Medical Technology Stock Letter. [gview file=http://www.bioinvest.com/wp-content/uploads/2014/09/MTSL-787-September-18-2014.pdf save=”1″]
Special ASH Update for ISIS ISIS Factor XI Data Published in NEJM, 2nd Time in One Week: Isis has been an unexpected star at ASH as they have released the final Phase II data for ISIS-FXI at ASH and were also published in the New England Medical Journal. The data showed a significant reduction (seven-fold[…]
November 16, 2014 Weighing the Week Ahead: Time to Buy Commodities? …..Other Advice Here is our collection of great investor advice for this week: Stock ideas! The very hot biotech sector has pulled back a bit. (For traders, Felix actually has it as one of the few sectors that is not worth a “fresh money†buy[…]
November 3, 2014 Biotech Bets: Cardio, Cancer, Vaccines, and Ebola Jay Silverman is a biotechnology stock analyst and an editor at the industry leading biotech newsletter, The Medical Technology Stock Letter. Here, he offers an in-depth look at three of his favorite biotech stocks. Steven Halpern: Our guest today is Jay Silverman, a biotech stock analyst with[…]
September 22, 2014 Five Prime: A Prime Play on Proteins By: John McCamant Following a recent meeting with top management at this firm, John McCamant—editor of The Medical Technology Stock Letter—has issued a buy recommendation for the early-stage biotech, noting that it could become a leader in immuno-oncology. Steven Halpern: Our guest today is John McCamant, the[…]
November 20, 2014 Below is a pdf for Issue 791 of the Medical Technology Stock Letter. [gview file=http://www.bioinvest.com/wp-content/uploads/2014/11/MTSL-791-Nov-20-2014.pdf save=”1″]
October 23, 2014 Below is a pdf for Issue 789 of the Medical Technology Stock Letter. [gview file=http://www.bioinvest.com/wp-content/uploads/2014/10/MTSL-789-October-23-2014.pdf save=”1″]
October 2, 2014 Below is a pdf for Issue 788 of the Medical Technology Stock Letter. [gview file=http://www.bioinvest.com/wp-content/uploads/2014/10/MTSL-788-October-2-2014f.pdf save=”1″]
September 4, 2014 Below is a pdf for Issue 786 of the Medical Technology Stock Letter. [gview file=http://www.bioinvest.com/wp-content/uploads/2014/09/MTSL-786-September-4-2014.pdf save=”1″]
